17,261 trials
Attention Deficit Hyperactivity Disorder
Primary: Mean Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Total Score During the Double-Blind Treatment Period — 12.81; 18.67 score on a scale — p=< 0.001
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Primary: Clinical Response to Crenolanib With Standard Salvage Chemotherapy — 7; 3; 4; 0 Participants
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With BIO 300 Oral Suspension-related Dose Limiting Toxicity — 0; 0; 0; 6 Participants
Maternal Opioid Use Disorder · Opioid Exposed Infant
Primary: Fetal Heart Rate at 24 Weeks — 143.64 beats per minute
Atherosclerosis · Adherence, Medication · Tolerance
Primary: Carotid Intimal Media Thickness — -0.017; -0.092 mm
Scleroderma, Systemic · Scleroderma, Diffuse · Sclerosis, Systemic
Primary: FT011 Levels in Plasma — 5.45; 10.3 ug/mL
Head and Neck Cancer
Primary: Median Laryngectomy-free Survival (LFS) — 11.1 months
Myasthenia Gravis
Primary: Double-Blind Treatment Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 5; 4; 5; 0 Participants
Gingival Inflammation
Primary: Incidence of Adverse Events — 19; 10; 3 Participants
Small Cell Lung Cancer · Extensive-stage Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 1.9; 1.7 Months
Pain · Cannabis · Opioid Use
Primary: Peak Cold Pressor Tolerance — 118.6; 130.8; 161.1; 163.2 minutes — p=0.195
Gastric Adenocarcinoma · Esophageal Adenocarcinoma · Metastasis
Primary: Best Objective Response Rate (bORR) — 61; 50 Percentage of participants
Peripheral Artery Disease
Primary: Number of Participants With Aneurysm Formation, Anastomotic Bleeding or Spontaneous Rupture, HAV Infection, HAV Removal, and Significant Inflammation at the HAV…
Nicotine Dependence, Cigarettes, Uncomplicated
Primary: Average Cigarettes Smoked Per Day — 4.3; 8.0 average cigarettes per day — p=.111
Submental Fat
Primary: Pharmacokinetics Measure - Drug Concentration in the Blood (ng/mL) — 487.7; 473.3 concentration (ng/ml)